CRSP vs BEAM
CRSP and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $5.01B | $2.40B |
| P/B | — | 2.25 |
| P/S | 1427.0x | 17.2x |
| Revenue | — | $156.03M(TTM) |
| Revenue growth (YoY) | -90.6% | 120.0% |
| Net income | — | -$86.52M(TTM) |
| Earnings growth (YoY) | -58.8% | 78.8% |
| EPS, diluted | — | $-0.69(TTM) |
| EBIT margin | -18933.6% | -274.6% |
| ROE | -33.3% | -7.5% |
| ROIC | -32.6% | -40.5% |
| 1y total return | -10.5% | +9.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: CRSP vs BEAM
| Metric | CRSP | BEAM |
|---|---|---|
| End value | $9.5K | $12.4K |
| Total return | -4.6% | +23.8% |
| CAGR | -0.7% | +3.3% |
| Volatility | 61.7% | 79.9% |
| Sharpe | 0.23 | 0.38 |
| Sortino | 0.35 | 0.59 |
| Max drawdown | -85.1% | -89.1% |
Based on 1660 common trading days, 2020-02-06 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)